The virtual screening of a library of chalcone derivatives led us to the identification of potential new MDM2 ligands. The chalcones with the best docking scores obeying the Lipinski rule of five were subsequently prepared by base-catalyzed aldol reactions. The activity of these compounds as inhibitors of p53–MDM2 interaction was investigated using a yeast-based screening assay. Using this approach two chalcones (3 and 4) were identified as putative small molecule inhibitors of p53–MDM2 interaction. The activity of both chalcones was further investigated in a panel of human tumor cells. Chalcones 3 and 4 revealed a pronounced tumor cell growth inhibitory effect on tumor cell lines. Additionally, chalcone 4 caused alterations in the cell cyc...
Ph.D. ThesisAs a principal gatekeeper, p53 is inactivated mutationally in over 50% of human cancer (...
Molecular docking study of 6 chalcone analogues with protein target from the crystallographic struct...
The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed tha...
The virtual screening of a library of chalcone derivatives led us to the identification of potential...
The p53 protein is one of the most important tumor suppressors that are frequently inactivated in ca...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A ...
Aim Chalcones are naturally occurring compounds with recognized anticancer activity. It was recently...
Intracellular pathogens, such as Chlamydia trachomatis, have been recently shown to induce degradati...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Ph.D. ThesisAs a principal gatekeeper, p53 is inactivated mutationally in over 50% of human cancer (...
Molecular docking study of 6 chalcone analogues with protein target from the crystallographic struct...
The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed tha...
The virtual screening of a library of chalcone derivatives led us to the identification of potential...
The p53 protein is one of the most important tumor suppressors that are frequently inactivated in ca...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A ...
Aim Chalcones are naturally occurring compounds with recognized anticancer activity. It was recently...
Intracellular pathogens, such as Chlamydia trachomatis, have been recently shown to induce degradati...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Ph.D. ThesisAs a principal gatekeeper, p53 is inactivated mutationally in over 50% of human cancer (...
Molecular docking study of 6 chalcone analogues with protein target from the crystallographic struct...
The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed tha...